Tuning Into Radiotherapeutics: Considerations for Oncology Trials

Presented by

Rupa Doshi, Ph.D., Vice President, Oncology Strategy ; Ashley Herrick, Ph.D., Executive Director, Oncology Program Strategy

About this talk

Radiopharmaceutical therapy is emerging as a safe and effective targeted approach to treating many types of cancer. Clinical trials for these therapies are complex requiring a multi-disciplinary approach and careful coordination to produce meaningful and conclusive results. In this webinar, we will look at the history and future trajectory of radiopharmaceuticals, describe their potential advantages, examine challenges specific to the development of these therapies, and identify key considerations for clinical trials, from meeting regulatory demands to recruiting patients. Topics will include: • How radiopharmaceuticals have evolved since 1903, when Alexander Graham Bell introduced the idea of placing radium-containing sources in or near tumors • What’s ahead: advances in production and availability of new isotopes, new imaging technologies, discovery of new targets, and more • Regulatory requirements, which differ considerably depending on geography Patient recruitment: overcoming misconceptions about exposure to radioactivity and management of travel for site visits and study assessments. Key Learning Objectives: • How radiopharmaceuticals have evolved • Advances in radiopharmaceuticals • Regulatory requirements • Patient Recruitment Questions? Contact info@premier-research.com
Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (96)
Subscribers (4594)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.